Director, The Gene Lay Institute of Immunology and Inflammation of Brigham and Women’s Hospital, Massachusetts General Hospital, and Harvard Medical School.
Samuel L. Wasserstrom Professor of Neurology, Harvard Medical School
Institute Member, Broad Institute of MIT and Harvard
FOCUS
Immunology, Neuroimmunology, Autoimmunity and Cancer Immunology
EDUCATION
BVSc - Bachelor of Veterinary Science (equivalent to D.V.M.) College of Veterinary Medicine, Haryana Agricultural University, Hisar, India. Graduated with honors. (1976)
Specialization in the field of "Veterinary Pathology." College of Veterinary Medicine, Haryana Agricultural University, Hisar, India. (1978)
PhD - Department of Pathology and Public Health, University of Queensland, St. Lucia, Brisbane, Australia. (1980-1985)
AWARDS AND ACOLADES
Ranbaxy Research Award in the field of Medical Research, Ranbaxy Scientific Foundation, New Delhi, India. (2011)
First recipient of the Samuel L. Wasserstrom chair in Neurology at Harvard Medical School, Boston, MA (2014)
Garber Lecture, French Society of Immunology (2014)
Distinguished Eberly Lecture, University of Pittsburg (2014)
Nobel Laureate Peter Doherty Lecture, St. Judes, Memphis, TN. (2014)
Newsom-Davis Lecture, International Society of Neuroimmunology (2016)
Dr. William E. Paul Distinguished Innovator Award, Lupus Research Alliance New York (2018)
MileStones in Research Award, National Multiple Sclerosis Society, Boston, Massachusetts (2019)
ICIS 2020 BioLegend William E. Paul Award, International Cytokine Society, Oradell, NJ (2020)
AAI 2021 Distinguished Fellow Award, American Association of Immunologists, Rockville, MD (2021)
Dystel Prize for MS Research, National Multiple Sclerosis Society and American Association of Neurology (2021)
AAI Thermo Fisher Meritorious Career Award, American Association of Immunologists, Rockville, MD (2025)
COMPANIES AND BOARDS
Founder - Bicara Pharmaceuticals (went public fall 2024), POINT Therapeutics, Tempero Pharmaceuticals (acquired by GSK), CoStim Pharmaceuticals (acquired by Novartis), Potenza Therapeutics (acquired by Astellas), Tizona Therapeutics (partly acquired by Gilead), Thrishula Therapeutics, Celsius Therapeutics (acquired by AbbVie), Larkspur Biosciences.
Scientific Advisory Board - Altru Bio, Comorin Therapeutics, Cell Signaling Technology; Elpiscience Biopharmaceutical Ltd, Larkspur, Noetik, Tr1X, Werewolf Therapeutics.
Board Positions - Biocon, Syngene International, Bicara Parmaceuticals, Zumutor